Davis Capital Management’s Cytek Biosciences CTKB Stock Holding History

Davis Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$53	Buy	+12	New	+$51	﹤0.01%	1200

Other funds holding CTKB

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Wealth Enhancement Advisory Services

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

NorthCrest Asset Manangement Plymouth, Minnesota $3.89B AUM 40.33% 1-Year Est. Return

Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Davis Capital Management's CTKB Position: Q2 2026 in Review

Davis Capital Management opened a new position in Cytek Biosciences (CTKB) in Q2 2026: 12 shares worth $53. The stake represents ﹤0.01% of the portfolio and ranks #1200 among its holdings.

9 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

Davis Capital Management held 12 shares of Cytek Biosciences worth $53 as of Q2 2026.
Cytek Biosciences was a new Davis Capital Management position in Q2 2026.
Cytek Biosciences made up ﹤0.01% of Davis Capital Management's portfolio in Q2 2026, its #1200 holding.
9 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Davis Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.